Strength: 7.5 mg
Packaging Size: 0.5 ml
Packaging Type: Insulin
Manufacturer: ZISKA
Shelf Life: 24 months
Usage/Application: Improves blood sugar control in adults with type 2 diabetes, when used alongside diet and exercise.

Storage Conditions: Store in a cool, dry place.

About Tizaro 7.5mg ( Tirzepatide) 7.5 mg Inn ):

Tizaro (tirzepatide) 7.5 mg per 0.5 mL is a highly effective injectable insulin for adults managing type 2 diabetes. It is specifically designed to enhance blood sugar (glucose) levels when used in conjunction with proper diet and regular exercise. Tizaro 7.5mg Injectable also shows potential in aiding weight loss, making it a versatile option for diabetes management.

Please note, the use of Tizaro in individuals with a history of pancreatitis has not been established.

Tizaro 7.5mg Key Benefits:

• Effective Blood Sugar Management: Helps improve glucose levels when combined with diet and exercise.
• Weight Loss Support: Known to assist in weight reduction, offering added benefits for diabetes patients.
• Convenient Packaging: Available in 0.5 ml insulin injections, ensuring precise dosage and ease of use.
• Long Shelf Life: 24-month shelf life ensures prolonged usability.

Tizaro 7.5mg Important Information:

• Consult with Your Healthcare Provider: Always seek advice from your healthcare provider before starting any new medication, especially if you have a history of pancreatitis.
• Storage Instructions: Keep Tizaro in a cool, dry place to maintain its efficacy.

Enhance your diabetes management with Tizaro 7.5mg Injectable, designed to support both blood sugar control and weight loss. Choose Tizaro for a comprehensive approach to your health.

The post Tizaro 7.5mg (Tirzepatide inn 7.5 mg) appeared first on BD Anticancer Drug Supplier.

Buy Olanib 150mg can also be prescribed for the treatment of malignant tumors in the later stages with metastases.

Composition and dosage form Olanib 150 mg

The active substance of the drug is Olaparib. It is made in capsules. Olanib is for oral use only. The capsule contains 150 mg of active ingredient. The package contains 120 tablets.

Indications for use Olanib 150 mg

The agent is an inhibitor of PARP (polymerase) and ADP-ribose. The active substance Olaparib suppresses PARP and cancer cells lose their ability to recover.

Assign a remedy for treatment:

• ovarian cancer;
• tumors of the fallopian tubes;
• some types of breast cancer;
• to solve other problems.

The use of Olanib is also shown for the treatment of ovarian cancer that has returned after chemotherapy. It can be prescribed in situations where it is impossible to perform operable treatment. Also used for late stages with metastasis.

Contraindications to the use of Olanib 150 mg

Suitable pharmacological agent for the treatment of not all categories of patients. The doctor prescribes Olanib after a detailed examination and study of the entire picture of the disease.

Contraindications:

• children under 18;
• pregnant women;
• breastfeeding women;
• patients with severe background diseases;
• patients with individual intolerance to the components of the drug.

Self-medication can adversely affect health.

Possible adverse reactions Olanib 150 mg

When the doctor’s recommendations are followed, side effects rarely occur. About 10% of people may experience mild to moderate ailments.

Possible adverse reactions:

• Defecation disorders: constipation, diarrhea.
• Increased fatigue.
• Headache, dizziness.
• Loss of appetite.
• Dyspepsia, etc.

In case of unpleasant symptoms, you should consult a doctor. Urgently seek help if you develop an allergic reaction, a temperature of 38 degrees or higher, a strong uncontrollable cough, or any other breathing problems.

Method of application and dosing regimen Olanib 150 mg

The dosage and treatment regimen is selected individually, depending on the type of malignant neoplasm and the stage of the disease.

Olanib is incompatible with certain medications, so the doctor should be informed if the patient is taking any other medications.

Features of the use of Olanib 150 mg

You should not bite or chew the capsules, you just need to swallow them whole with water. It is forbidden to independently change the dose of use. In case of an overdose, the patient should immediately contact their doctor or go to the hospital.

With alcohol, the use of Olanib is unacceptable. There is a possibility of adverse reactions, it is not recommended to work with complex mechanisms or drive a car during treatment. The medicine is dispensed by prescription. The drug should be stored in a dry, dark place. You can order and buy Olanib from BD anti cancer Drug store.

The post Olanib 150mg (Olaparib) appeared first on BD Anticancer Drug Supplier.

Ingredients: Tucatinib 150mg
Brand: Tucaxen
Manufacturer: Everest Bangladesh
Specification: box of 30 tablets

Who is Tucaxen Tucatinib 150mg indicated for?

Tucaxen Tucatinib 150mg is used in combination with trastuzumab and capecitabine to treat advanced breast cancer with HER2 metastasis (cancer that has spread to include the brain) or cancer that cannot be removed by surgery in patients with breast cancer. patients who have received one or more anti-HER2 breast cancer therapies. It belongs to a group of drugs, known as anticancer drugs.
Tucaxen 150 interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells can also be affected by the drug, other undesirable effects will also occur. Some of these can be serious and must be reported to your doctor.
Patients take this medication as directed by their doctor.

Tucaxen drug Tucatinib 150mg not used for which subjects?

When deciding to use Tucaxen, the risks of taking the drug must be weighed against the benefits it offers. This is a decision that you and your doctor will make. For this medication, the following should be considered:

People with allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this or any other medicine. Also tell your healthcare professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For over-the-counter products, read the label or package ingredients carefully.
Pediatrics
Appropriate studies have not been performed on the relationship of age to the effects of tucatinib in the pediatric population. Safety and effectiveness have not been established.

Geriatrics

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of tucatinib in the elderly. However, elderly patients are more likely to experience more serious adverse events (eg, diarrhea, nausea and vomiting), which may require caution in patients receiving this medicine.

Breastfeeding Women

There are no adequate studies in women to determine infant risk when using this medicine during breast-feeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Drug interactions

Although certain medicines should not be used together, in other cases two different medicines may be used together even if an interaction may occur. In these cases, your doctor may want to change your dosage or take other precautions that may be needed. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using Tucaxen Tucatinib 150mg with any of the following medicines is generally not recommended, but may be needed in some cases. If both medicines are prescribed together, your doctor may change how much or how often you use one or both medicines
Abametapir
Abiraterone Acetate
Alfentanil
apalutamide
Carbamazepine
Clopidogrel
Cyclosporine
Deferasirox
Digoxin
Dihydroergotamine
Dofetilide
Enzalutamide
Ergotamine
Fedratinib
Fentanyl

Side Effects:
The most common adverse reactions are:

Diarrhea, hand-foot syndrome, nausea, fatigue, liver problems, vomiting, mouth sores/ pain, weight loss, muscle/ joint pain, loss of appetite, abdominal pain, headache, anemia, and rash.

The above information comes from the Internet. Please consult with a doctor for medical advice.

Suggestion:
* Any advice on the use of the drug is for reference only. Please consult with a doctor for medical advice. All Names, logos, and trademarks are the property of their respective owners: watermarks and QR codes are used for identification purposes only.

The post Tucaxen 150mg (Tucatinib) appeared first on BD Anticancer Drug Supplier.

• Sotoxen 120mg (Sotorasib) is a drug manufactured by Everest Pharmaceuticals – Bangladesh, with the main ingredient Sotorasib has the effect of treating locally advanced or metastatic non-small cell lung cancer, the drug helps prevent cancer cells. develop and spread.

Ingredients of Sotoxen 120mg (Sotorasib)

• Sotorasib 120mg.

Dosage forms

• Tablets.

What is lung cancer?

• Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs, usually cells in the lining of the airways. These abnormal cells do not develop into healthy lung tissue but divide rapidly and form tumors that interfere with lung function.

Uses and indications of Sotoxen 120mg (Sotorasib)

• Sotoxen 120mg (Sotorasib) is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) caused by KRAS G12C in adults who have received at least one prior systemic therapy.

Dosage – Dosage of Sotoxen 120mg (Sotorasib)

• How to use:
  • Drugs for oral use
• Dosage:
  • Medicines used as prescribed by the doctor.

Contraindications of Sotoxen 120mg (Sotorasib)

• Do not use for people who are sensitive to any of the ingredients.

Precautions while using Sotoxen 120mg (Sotorasib)

• Use with caution in women who are pregnant or planning to become pregnant
• Use caution in patients with liver problems
• People with lung or breathing problems other than lung cancer

Use for pregnant or lactating women

• Pregnant or lactating women consult a doctor

Use for drivers and machine operators

• Use caution when using the drug with subjects who drive and operate heavy machinery, because the drug can cause dizziness, loss of ataxia, ..

Side effects of Sotoxen 120mg (Sotorasib)

• Get emergency medical help if you have signs of an allergic reaction: hives; shortness of breath; swelling of the face, lips, tongue, or throat.
• Sotoxen 125mg (Sotorasib) can cause fatal breathing problems. Get emergency medical help if you have a new or worsening fever, cough, or shortness of breath.
• Severe persistent nausea, vomiting or diarrhea;
• liver problems–nausea, vomiting, loss of appetite, stomach pain (upper right), fatigue, bruising or bleeding, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes ).
• Frequent:
  • Nausea, diarrhea;
  • Cough;
  • Life problems;
  • Pain in bones, joints, or muscles;
  • Weariness.

• Inform your doctor about unwanted effects encountered when using.

Interact

• Acid reducing agent:
  • Concomitant administration of Sotorasib 120mg with gastric acid reducers reduces sotorasib concentrations, which may decrease the effectiveness of sotorasib. Avoid co-administration of LUMAKRAS with proton pump inhibitors (PPIs), H2-receptor antagonists and locally acting antacids. If co-administration with an antacid cannot be avoided, administer Sotorasib 120mg 4 hours before or 10 hours after a topical antacid
• Strong CYP3A4 Inducers:
  • Co-administration of Sotorasib 120mg with a strong CYP3A4 inducer reduces sotorasib concentrations which may decrease the effectiveness of sotorasib. Avoid co-administration of Sotorasib 120mg with strong CYP3A4 inducers.

• Effect of Sotorasib 120mg on other medicines
  • CYP3A4 Substrates
    Co-administration of Sotorasib 120mg with a CYP3A4 substrate reduces its plasma concentrations, which may decrease the effectiveness of the substrate. Avoid co-administration of Sotorasib 120mg with CYP3A4-sensitive substrates, as minimal concentration changes may lead to substrate therapy failure. If co-administration cannot be avoided, increase the dose of the sensitive CYP3A4 substrate according to its Prescribing Information.
  • P-Glycoprotein (P-gp) Substrates
    Co-administration of Sotorasib 120mg with P-gp substrate (digoxin) increases plasma concentrations of digoxin, possibly increasing the adverse reactions of digoxin. Avoid co-administration of Sotorasib 120mg with a P-gp substrate where minimal concentration changes can lead to serious toxicity. If co-administration cannot be avoided, reduce the dose of the P-gp substrate in accordance with its Prescribing Information.

Overdose and treatment

• If an overdose occurs, notify your doctor immediately, or if you see unusual symptoms, you need to go to the hospital for timely treatment.

Preserve

• Store at a cool temperature below 30 degrees Celsius.
• Keep out of reach of CHILDREN.

Packing

• Box of 56 tablets.

Producer

• Everest Pharmaceuticals – Bangladesh.

The post Sotoxen 120mg (Sotorasib) appeared first on BD Anticancer Drug Supplier.

Ventoxen (Venetoclax), the generic form of Venclexta, is a prescription medication used to treat adult patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML). Venetoclax works by slowing down or stopping the growth of cancer cells.

This medication is manufactured by Everest Pharma Ltd. in Bangladesh.

Administration Instructions:

Ventoxen should be taken orally once daily with a meal and water, at approximately the same time each day.

Side Effects:

The most common adverse reactions associated with Ventoxen include:

• Diarrhea
• Nausea
• Vomiting
• Tiredness
• Headache

Please note that the information provided is sourced from the internet. It is essential to consult with a doctor for personalized medical advice.

Disclaimer:

• Any advice on the use of this medication is for reference purposes only. Consult with a healthcare professional for personalized medical advice. All names, logos, and trademarks are the property of their respective owners. Watermarks and QR codes are used for identification purposes only.

The post Ventoxen 100mg (Venetoclax) appeared first on BD Anticancer Drug Supplier.

Brand: Incepta Pharmaceuticals

Mantle Cell Lymphoma: Ibrutinib is indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia.

Waldenstrom Macroglobulinemia (WM): Ibrutinib is indicated for the treatment of patients with Waldenstrom Macroglobulinemia (WM).

Marginal Zone Lymphoma: Ibrutinib is indicated for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD 20-based therapy.

• Take according to the doctor’s advice
• Therapeutic Class
• Targeted Cancer Therapy
• Pharmacology

Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in the activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
Dosage
Mantle Cell Lymphoma and Marginal Zone Lymphoma: The recommended dose of Ibrutinib for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia (WM): The recommended dose of Ibrutinib for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity. The recommended dose of Ibrutinib for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
*Take according to the doctor’s advice
Administration
Administer Ibrutinib orally once daily at approximately the same time each day.
Swallow the capsules whole with water. Do not open, break, or chew the capsules.
*Take according to the doctor’s advice
Interaction
CYP3A Inhibitors: Co-administration with strong and moderate CYP3A inhibitors should be avoided. If a moderate CYP3A inhibitor must be used, Ibrutinib dose should be reduced

CYP3A Inducers: Co-administration with strong CYP3A inducers should be avoided
Contraindications
Hypersensitivity to the active substance or to any of the excipients.

Side Effects
The following adverse reactions are discussed in more detail in other sections of the labeling: Hemorrhage, Infections, Cytopenias, Atrial Fibrillation, Hypertension, Second Primary Malignancies and Tumor Lysis Syndrome. Additional Important Adverse Reactions: Diarrhea, Visual Disturbance.

Pregnancy & Lactation

Pregnancy: Ibrutinib, a kinase inhibitor, can cause fetal harm based on findings from animal studies. In animal reproduction studies, administration of Ibrutinib to pregnant rats and rabbits during the period of organogenesis at exposures up to 2-20 times the clinical doses of 420-560 mg daily produced embryofetal toxicity including malformations. If Ibrutinib is used during pregnancy or if the patient becomes pregnant while taking Ibrutinib, the patient should be apprised of the potential hazard to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Lactation: There is no information regarding the presence of Ibrutinib or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.

Overdose Effects

There is no specific experience in the management of Ibrutinib overdose in patients. One healthy subject experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) after a dose of 1680 mg. Closely monitor patients who ingest more than the recommended dosage and provide appropriate supportive treatment.

Use in Special Population
Pediatric Use: The safety and effectiveness of Ibrutinib in pediatric patients has not been established.

Geriatric Use: Of the 905 patients in clinical studies of Ibrutinib, 62% were ≥ 65 years of age, while 21% were ≥75 years of age. No overall differences in effectiveness were observed between younger and older patients. Anemia (all grades) and Grade 3 or higher pneumonia occurred more frequently among older patients treated with Ibrutinib.

Hepatic Impairment: Ibrutinib is metabolized in the liver. In a hepatic impairment study, data showed an increase in Ibrutinib exposure. The safety of Ibrutinib has not been evaluated in cancer patients with mild to severe hepatic impairment by the Child-Pugh criteria. Monitor patients for signs of Ibrutinib toxicity and follow dose modification guidance as needed. It is not recommended to administer Ibrutinib to patients with moderate or severe hepatic impairment.
Storage Conditions
Store in a dry place below 30°C, and protect from light. Keep out of the reach of children.

The post Ibrucent 140 Mg (Ibrutinib) appeared first on BD Anticancer Drug Supplier.

Brand: Incepta Pharmaceuticals

Indications
Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
*
Therapeutic Class
Cytotoxic Chemotherapy
Pharmacology
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, osimertinib is specific for the gate-keeper T790M mutation which increases ATP binding activity to EGFR and results in a poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.
Dosage
The recommended dose of Osimertinib is 80 mg once a day until disease progression or unacceptable toxicity. Osimertinib can be taken with or without food. If a dose of Osimertinib is missed, do not make up the missed dose and take the next dose as scheduled.
*
Administration
Administration To Patients Who Have Difficulty Swallowing Solids: Disperse the tablet in 60 ml (2 ounces) of non-carbonated water only. Stir until the tablet is dispersed into small pieces (the tablet will not completely dissolve) and swallow immediately. Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 120 ml to 240 ml (4 to 8 ounces of) water and immediately drink.

If administration via a nasogastric tube is required, disperse the tablet as above in 15 ml of non-carbonated water, and then use an additional 15 ml of water to transfer any residues to the syringe. The resulting 30 ml liquid should be administered as per the nasogastric tube instructions with appropriate water flushes (approximately 30 ml).
*
Interaction
Strong CYP3A4 Inducers: If concurrent use is unavoidable, increase Osimertinib dosage to 160 mg daily when coadministering with a strong CYP3A inducer. Resume Osimertinib at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer
Side Effects
Common side effects are Interstitial Lung Disease or Pneumonitis, QTc Interval Prolongation, Cardiomyopathy, Keratitis
Pregnancy & Lactation
Use in Pregnancy: There is no or limited amount of data on the use of Osimertinib in pregnant women. Studies in animals have shown reproductive toxicity. Based on its mechanism of action and preclinical data, Osimertinib may cause foetal harm when administered to a pregnant woman. Administration of osimertinib to pregnant rats was associated with embryolethality, reduced foetal growth and neonatal death at exposures similar to what is expected in humans. Osimertinib is not recommended during pregnancy and in women of childbearing potential not using contraception.

Use in Lactation: It is not known whether osimertinib or its metabolites are excreted in human milk. Administration to rats during gestation and early lactation was associated with adverse effects, including reduced growth rates and neonatal death. There is insufficient information on the excretion of osimertinib or its metabolites in animal milk. A risk to the suckling child cannot be excluded. Breastfeeding should discontinue during treatment with Osimertinib.

Fertility: There are no data on the effect of Osimertinib on human fertility. Results from animal studies have shown that Osimertinib has effects on male and female reproductive organs and could impair fertility
Storage Conditions
Store Osimertinib at room temperature between 20°C to 25°C. Safely throw away medicine that is out of date or that you no longer need. Keep Osimertinib and all medicines out of the reach of children.

The post Osicent 80 Mg (Osimertinib) appeared first on BD Anticancer Drug Supplier.

CABOXEN 20 capsules contain Ceboa? Nib (S/malate INN equivalent to 20 mg Cabozantinib.

CABOXEN 80 capsule: Each capsule contains Cabozantinib (TS)-malate INN equivalent to 80 mg of Cabozantinib.

CLINICAL PHARMACOLOGY
Mechanism of Action
In Vida biochemical and/or cellular assays have shown that Cabozantinib inhibits the tyrosine kinase activity of MET, ET, VEGFR-1, -2 and -3, AXL, FiET, PO’21, TYRO3, MeFi, KIT, TFiKB,
FLT-3, and TIE-2. In tumor microenvironments, receptor tyrosine kinases are involved in oncogenes, metastasis, tumor angiogenesis, and drug resistance.

NONCLINICAL TOXICOLOGY
Cemlnogenesl¥, Mutagenesle, impelrmeM of 6eniiKy
The carcinogenic potential of Cabozantinib has been evaluated in two species ratio transgenic mice and Sprague-Dswïey rate. Once-daily oral administration of Cebozant! A dose of mg/kg resulted in a significantly increased incidence of malignant and complex malignant pheochromocytomas in combination with benign pheochromocytomas, or in benign pheochromocytomas alone in male rats
baseline or resolution to Grade ), reduce the dose as follows:

I previously received a 140 mg daily dose, now receiving 100 mg daily (one 80-mg and one 20-mg capsule).
II previously receiving 100 mg daily dose, resume treatment al 60 mg daily (three 20-mg capsules)
In case of the previous 60 mg daily dose, resume at 6Q mg if tolerated, otherwise, discontinue:
Development of steel perforation or f! Studs formation
Severe hemorrhage
Serious arterial thromboembolic event (e g., myocardial infarction, cerebral infarction)
Nephroiio síndrome
Uncontrolled hypertension despite optimal medical management.

Osteonecrosis of the ¡aw
Reversible posterior leukoenoephalopaihy síndrome
In Patients Concurrently T¥klng ¥ Strong CYRsA4 Inhlbhor
Reduce Cabozantinib dosage by 40 mg daily (for example, from 40 mg to 60 mg daily).

Proteinuria
was observed in 4 of the patients 0abozan- lining, including one with es ed lo none of
receiving placebo. urine
Cabozantinib treatment. Cabozanlinib pacients

RsverslbN Posterior Lo ikosnoaphelopathy rome
Reversible Leukoencephalopathy a

Pregnancy
Based on findings of home enamel Mudie’s and its mechanism of action, cabozantinib can cause fetal harm when administered to a pregnant woman. There are no available data on pregnant women to inform In animal dweloprrieMal and reproductive toxicology Mudie’s administration d lzenànio o pregnant rate and rabbis during organogenesis resulted in embryofetal lethality and structural anomalies at exposures Prat were below those occur ring clinically at the recommended dose. pregnant women or women of the childbearing potential of the potential hazard to a fetus

human exposure by AUC at the recommended 60 mg dose).
Cabozantinib was not carcinogenic in a 26-week carcinogenicity study in RasH2 transgenic mice at a slightly higher exposure than the intended human therapeutic exposure.

Cabozantinib was not mutagenic in vitro in the bacterial reverse
Resume the dose that was used prior to initiating the CYP3A4 inhibitor 2 to 3 days after discontinuation of the strong inhibitor. In Patients Concurrently Taking a Strong CYP3A4 Inducer, increase the daily cabozantinib dose by 40 mg (for example, from 140 mg to 180 mg daily or from 100 mg to 140 mg daily).

Manufactured by
Everest Pharmaceuticals Ltd.

The post Caboxen 20 Mg (Cabozantinib) appeared first on BD Anticancer Drug Supplier.

Active ingredient: Lenvatinib 4mg, 10mg.

Specification: Box of 30 tablets.

Origin: Everest Bangladesh.

Drug registration number: Updating.

What are the uses of Lenvaxen? mechanism?

Lenvaxen contains lenvatinib which is a receptor tyrosine kinase (RTK) inhibitor. Drugs that selectively act on the kinase activities of the vascular endothelial growth factors (VEGF) VEGFR1 (FLT1), VEGFR2 (KDR) and related VEGFR3 (FLT4) RTK including fibroblast growth factor receptor (FGF) FGFR1, 2, 3 and 4, platelet-derived growth factor (PDGF) receptor PDGFRα, KIT and RET.

In addition, lenvatinib’s selective, direct antiproliferative activity in hepatocyte lines depends on activated FGFR signaling, is attributed to lenvatinib’s inhibition of FGFR signaling.

Although not directly studied with lenvatinib, the mechanism of action (MOA) for hypertension is thought to be mediated by inhibition of VEGFR2 in vascular endothelial cells.

Similarly, although not directly studied, MOA for proteinuria is required to be regulated by upregulation of VEGFR1 and VEGFR2 in glomerular cells.

Dosage and how to use Lenvaxen 4?

• Dosage for HCC:   12 mg orally, once daily (for adults weighing > _60 Kg). 8 mg orally, once a day for adult weight
• Treatment of differentiated thyroid cancer : 24 mg orally, once a day
• Treatment of kidney cancer : 18 mg lenvatinib + 5 mg everolimus, orally, once a day.

In patients with severe renal or hepatic impairment, the dose is 14 mg once daily in thyroid cancer and 10 mg once daily in renal cancers <60.

Lenvaxen 10 . side effects

The most common side effects of Lenaxen in people being treated for thyroid cancer include :

1. fatigue 2. muscle aches and pains 3. weight loss

4. sore throat 5. stomachache 6. stomachache

7. loss of appetite 8. nausea 9. headache

10.Redness, itching or peeling skin on your hands and feet 11. Hoarseness

The most common side effects of Lenvaxen in people being treated for kidney cancer include:

• 1. fatigue 2. loss of appetite 3. nausea
• 4. swelling in your hands and feet 5. stomach (abdominal) pain 6. rash.
• 7. pain and muscle pain 8. causes sores
• 10. cough, 11. difficulty breathing 12. weight loss.

Lenvaxen can cause fertility problems in men and women.

Drug interactions

Lenvatinib can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV .

Other drugs may affect lenvatinib, including prescription and over-the-counter medicines, vitamins, and herbal products.

Tell your doctor about all your current medicines and any you start or stop using.

Tell your doctor if you have ever:

• heart disease, high blood pressure;
• heart attack, heart failure, stroke, or blood clot;
• headache or vision problems;
• bleeding problems;
• perforation (a hole or tear) in your stomach or intestines;
• seizure disorder;
• kidney disease; or liver disease.

You may need to have a negative pregnancy test before starting this treatment. Do not use lenvatinib if you are pregnant. It can harm an unborn baby.

Use effective birth control to prevent pregnancy while you are using lenvatinib and for at least 30 days after your last dose.

The post Lenvaxen 4 mg and 10 mg (Lenvatinib) appeared first on BD Anticancer Drug Supplier.